Cytomegalovirus (CMV) is characterized by lifelong latent infection following primary infection. Prevalence of viral carriage in adult populations is high. Infections with CMV in immunocompetent persons are usually asymptomatic, but in the immunocompromised patient, primary infection or reactivation of latent infection may be severe.
Efalizumab is a humanized monoclonal antibody that blocks lymphocyte activation and migration. We describe herein a case of CMV infection occurring in a patient with psoriasis who was undergoing efalizumab therapy.